Clinical Trials Browser

Adenocarcinoma of Lung, Lung Neoplasms

Bile Duct Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Resectable Intrahepatic Cholangiocarcinoma

Breast Neoplasms, Triple Negative Breast Neoplasms

Gallbladder Cancer Unresectable

Triple Negative Breast Neoplasms

Neoplasm Metastasis

Adenocarcinoma, Carcinoma, Esophageal Neoplasms, Stomach Neoplasms

Carcinoma, Hepatocellular

Ovarian Neoplasms

Carcinoma, Non-Small-Cell Lung

Esophageal Neoplasms

Cholangiocarcinoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Cholangiocarcinoma

Carcinoma, Hepatocellular

Small Cell Lung Carcinoma

Lung Neoplasms, Small Cell Lung Carcinoma

Bile Duct Neoplasms, Cholangiocarcinoma

Limited Stage Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Hepatocellular

Non-Muscle Invasive Bladder Neoplasms

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

Small Cell Lung Carcinoma

Advanced Biliary Tract Carcinoma

Hepato Cellular Carcinoma

Leukemia, Lymphocytic, Chronic, B-Cell

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Colorectal Neoplasms

Lung Neoplasms

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

Lung Neoplasms, Small Cell Lung Carcinoma

Lung Neoplasms

Carcinoma, Hepatocellular

Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Hepatocellular

Adenocarcinoma, Stomach Neoplasms

Carcinoma, Hepatocellular, Liver Cirrhosis

Extensive Stage Small Cell Lung Cancer

Non Small Cell Lung Cancer NSCLC

Urinary Bladder Neoplasms

Carcinoma, Hepatocellular

Non-small-cell Lung Cancer Patients

Cholangiocarcinoma

Carcinoma, Hepatocellular

Carcinoma, Ovarian Epithelial

Clinical Trials

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Ablatio

NeoCOAST-2

Testing the Combination of the Anticancer Drug Durvalumab With Chemotherapy (Gemcitabine and Cisplatin) at Improving Outcomes for High-Risk Resectable Liver Cancer Before Surgery

DIAMOND

GCND

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

DG-03

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

IPROC

CONVERGE

PALEO

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

I-SPY

Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)

IOSPHERE

MOZART

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

TIGOS-LS

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

SLIDE-HCC

ENHANCE

Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC

Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study

TACTIC

IIT2025-03-YANG-LIFT-HCC

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)

HAIC-quad

Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

Durvalumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Stage HCC

Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

Ph2 Study of Savolitinib and Durvalumab (MEDI4736) Combination in Advanced MET Amplified Gastric Cancer(VIKTORY-2)

Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

AUSTRAL

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma

Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab

Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma

ZENOBIA

WoO